Concordance of Neuropathologic Diagnosis of Lewy Body Disease with Baseline Alpha-Synuclein Seed Amplification Assay in PPMI
Objective: To determine whether the alpha-synuclein seed amplification assay (aSyn-SAA) performed on cerebral spinal fluid (CSF) collected at the baseline (BL) PPMI visit is concordant…α-Synuclein Pathology Across Movement Disorders and Neurodegenerative Diseases by Seed Amplification Assay
Objective: To assess the frequency of pathological α-synuclein (αSyn) in various movement disorders and neurodegenerative diseases from a specialized movement disorder clinic by αSyn seed…Case Report: An Unusual Case of Corticobasal Syndrome
Objective: To describe a patient with corticobasal syndrome (CBS) and biomarker evidence of multiple proteinopathies. Background: CBS is a clinically heterogeneous syndrome caused by several…Ultrasensitive detection of aggregated α-synuclein using quiescent seed amplification assay for the diagnosis of Parkinson’s Disease
Objective: To develop a technology capable of ultra-sensitive, in situ amplification of abnormal conformations of αSyn within biological samples, potentially enhancing diagnostic accuracy and shedding…Parkinson’s Disease Risk Genotypes at the GPNMB Locus Associate with Extent of Post-mortem Lewy Pathology
Objective: To determine whether Parkinson’s disease (PD) risk genotypes at the GPNMB locus associate with distribution of Lewy pathology in brain samples from a spectrum…Genetic determinants of the progression of Lewy body pathology
Objective: To identify genetic risk factors associated with the distribution of Lewy body (LB) and Alzheimer’s disease (AD) co-pathology in the Lewy body disease (LBD)…The contribution of Brain Bank for Aging Research to pathomechanism of Parkinson’s disease
Objective: Objective: The aim of this paper is to present the result of the whole body screening of Lewy body pathology by Brain Bank for…Falls in Mild Cognitive Impairment with Lewy bodies (MCI-LB).
Objective: to identify clinical, physical activity and mobility measures that differentiate patients with mild cognitive impairment with Lewy bodies (MCI-LB) fallers and non-fallers from cognitively…A human tissue engineered nigrostriatal system as a testbed for understanding PD pathophysiology and therapeutic development
Objective: The objective of these studies is to develop a tissue engineered nigrostriatal system involving human dopaminergic and striatal cells to recapitulate many of the…In vivo positive amyloid PET in a patient with PDD, always reliable?
Objective: To describe a singular case of an early-onset Parkinson disease (PD) patient with PD dementia who presented in vivo positive 18 F-Flutebetamol PET but…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 10
- Next Page »